Skip to main content
SpringerLink
Log in

Risk Factors for Medication-Related Osteonecrosis of the Jaw

  • Chapter
  • First Online:
Book cover Medication-Related Osteonecrosis of the Jaws

Abstract

The clinician should attempt to determine the risk factors for a disease before treatment in order to prevent disease development. Even though numerous clinical case series have reported Medication-related osteonecrosis of the jaw (MRONJ) after intravenous or oral route administration of bisphosphonates (BPs), evidence-based research regarding risk factors is sparse. Currently, the route of administration, dose and duration of intake, nitrogen-containing BPs, and dental infection/dental invasive procedures can be suggested as risk factors for MRONJ. Recently, a human monoclonal antibody inhibiting osteoclasts, denosumab, has been introduced as an antiresorptive drug. The reported risk of denosumab-related osteonecrosis of the jaw (DRONJ) seems similar or slightly higher compared with intravenous intake of nitrogen-containing BPs. Dental extractions and oncological dosing could be related to an increased risk of DRONJ. There are also increasing reports of osteonecrosis of the jaw related with antiangiogenic chemotherapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Marx RE. Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg. 1983;41(5):283–8.

    CAS  PubMed  Google Scholar 

  2. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws–2009 update. J Oral Maxillofac Surg. 2009;67(5 Suppl):2–12.

    PubMed  Google Scholar 

  3. Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis. 2008;14(3):277–85.

    CAS  PubMed  Google Scholar 

  4. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115–7.

    PubMed  Google Scholar 

  5. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21(22):4253–4.

    PubMed  Google Scholar 

  6. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med. 2005;34(2):120–3.

    CAS  PubMed  Google Scholar 

  7. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res. 2002;8(5):1080–4.

    CAS  PubMed  Google Scholar 

  8. Conte P, Coleman R. Bisphosphonates in the treatment of skeletal metastases. Semin Oncol. 2004;31(5 Suppl 10):59–63.

    CAS  PubMed  Google Scholar 

  9. Ferretti G, Fabi A, Carlini P, Papaldo P, CordialiFei P, Di Cosimo S, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology. 2005;69(1):35–43.

    CAS  PubMed  Google Scholar 

  10. Metcalf S, Pandha HS, Morgan R. Antiangiogenic effects of zoledronate on cancer neovasculature. Future Oncol. 2011;7(11):1325–33.

    CAS  PubMed  Google Scholar 

  11. Kapitola J, Zak J. Effect of pamidronate on bone blood flow in oophorectomized rats. Physiol Res. 1998;47(4):237–40.

    CAS  PubMed  Google Scholar 

  12. Landesberg R, Woo V, Cremers S, Cozin M, Marolt D, Vunjak-Novakovic G, et al. Potential pathophysiological mechanisms in osteonecrosis of the jaw. Ann N Y Acad Sci. 2011;1218:62–79.

    CAS  PubMed  Google Scholar 

  13. Reid IR. Osteonecrosis of the jaw: who gets it, and why? Bone. 2009;44(1):4–10.

    CAS  PubMed  Google Scholar 

  14. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006;35(3):155–60.

    PubMed  Google Scholar 

  15. Yamashita J, Koi K, Yang DY, McCauley LK. Effect of zoledronate on oral wound healing in rats. Clin Cancer Res. 2011;17(6):1405–14.

    CAS  PubMed Central  PubMed  Google Scholar 

  16. Little DG, Peat RA, McEvoy A, Williams PR, Smith EJ, Baldock PA. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res. 2003;18(11):2016–22.

    CAS  PubMed  Google Scholar 

  17. Agarwala S, Jain D, Joshi VR, Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford). 2005;44(3):352–9.

    CAS  Google Scholar 

  18. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. J Bone Joint Surg Am. 2005;87(10):2155–9.

    PubMed  Google Scholar 

  19. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63(11):1567–75.

    PubMed  Google Scholar 

  20. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 2006;7(6):508–14.

    CAS  PubMed  Google Scholar 

  21. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479–91.

    PubMed  Google Scholar 

  22. AAOMS. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65(3):369–76.

    Google Scholar 

  23. Wimalawansa SJ. Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf. 2008;7(4):491–512.

    CAS  PubMed  Google Scholar 

  24. 2014 Position Paper on Medication Related Osteonecrosis of the Jaws, http://www.aaoms.org/docs/position_papers/mronj_position_paper.pdf?pdf=MRONJ-Position-Paper.

  25. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61(9):1104–7.

    CAS  PubMed  Google Scholar 

  26. Kuhl S, Walter C, Acham S, Pfeffer R, Lambrecht JT. Bisphosphonate-related osteonecrosis of the jaws–a review. Oral Oncol. 2012;48(10):938–47.

    CAS  PubMed  Google Scholar 

  27. Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract. 2012;12(3 Suppl):233–47.

    PubMed  Google Scholar 

  28. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–34.

    PubMed  Google Scholar 

  29. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23(34):8580–7.

    PubMed  Google Scholar 

  30. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65(3):415–23.

    PubMed  Google Scholar 

  31. Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, et al. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008;9(12):1166–72.

    PubMed  Google Scholar 

  32. Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, et al. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol. 2012;35(4):386–92.

    PubMed  Google Scholar 

  33. Zavras AI. The impact of bisphosphonates on oral health: lessons from the past and opportunities for the future. Ann N Y Acad Sci. 2011;1218:55–61.

    CAS  PubMed  Google Scholar 

  34. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144(10):753–61.

    CAS  PubMed  Google Scholar 

  35. Ezra A, Golomb G. Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. Adv Drug Deliv Rev. 2000;42(3):175–95.

    CAS  PubMed  Google Scholar 

  36. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et al. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab. 2010;28(4):365–83.

    CAS  PubMed  Google Scholar 

  37. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91(7):1191–200.

    CAS  PubMed  Google Scholar 

  38. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346(9):653–61.

    CAS  PubMed  Google Scholar 

  39. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol. 2006;134(6):620–3.

    CAS  PubMed  Google Scholar 

  40. Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist. 2008;13(8):911–20.

    PubMed  Google Scholar 

  41. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44(9):857–69.

    CAS  PubMed  Google Scholar 

  42. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91(7):968–71.

    CAS  PubMed  Google Scholar 

  43. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23(6):826–36.

    CAS  PubMed  Google Scholar 

  44. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27(32):5356–62.

    CAS  PubMed  Google Scholar 

  45. Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol. 2007;18(12):2015–9.

    CAS  PubMed  Google Scholar 

  46. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19(1):80–100.

    CAS  PubMed  Google Scholar 

  47. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377–87.

    CAS  PubMed  Google Scholar 

  48. Then C, Horauf N, Otto S, Pautke C, von Tresckow E, Rohnisch T, et al. Incidence and risk factors of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients having undergone autologous stem cell transplantation. Onkologie. 2012;35(11):658–64.

    CAS  PubMed  Google Scholar 

  49. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18(2):75–85.

    CAS  PubMed  Google Scholar 

  50. Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol. 2009;112(3):605–9.

    CAS  PubMed  Google Scholar 

  51. ADA. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006;137(8):1144–50.

    Google Scholar 

  52. Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg. 2010;68(2):243–53.

    PubMed  Google Scholar 

  53. Fellows JL, Rindal DB, Barasch A, Gullion CM, Rush W, Pihlstrom DJ, et al. ONJ in two dental practice-based research network regions. J Dent Res. 2011;90(4):433–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  54. Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, et al. Risk factors for osteonecrosis of the jaws: a case–control study from the CONDOR dental PBRN. J Dent Res. 2011;90(4):439–44.

    CAS  PubMed Central  PubMed  Google Scholar 

  55. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol. 2010;136(8):1117–24.

    CAS  PubMed  Google Scholar 

  56. Otto S, Abu-Id MH, Fedele S, Warnke PH, Becker ST, Kolk A, et al. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence–a multi-centre study. J Craniomaxillofac Surg. 2011;39(4):272–7.

    PubMed  Google Scholar 

  57. Urade M, Tanaka N, Furusawa K, Shimada J, Shibata T, Kirita T, et al. Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan. J Oral Maxillofac Surg. 2011;69(11):e364–71.

    PubMed  Google Scholar 

  58. Di Fede O, Fusco V, Matranga D, Solazzo L, Gabriele M, Gaeta GM, et al. Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: a retrospective multi-hospital-based study of 87 Italian cases. Eur J Intern Med. 2013;11.

    Google Scholar 

  59. Manfredi M, Merigo E, Guidotti R, Meleti M, Vescovi P. Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. Int J Oral Maxillofac Surg. 2011;40(3):277–84.

    CAS  PubMed  Google Scholar 

  60. Marx RE, Cillo Jr JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65(12):2397–410.

    PubMed  Google Scholar 

  61. O’Ryan FS, Lo JC. Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes. J Oral Maxillofac Surg. 2012;70(8):1844–53.

    PubMed  Google Scholar 

  62. Fleisher KE, Jolly A, Venkata UD, Norman RG, Saxena D, Glickman RS. Osteonecrosis of the jaw onset times are based on the route of bisphosphonate therapy. J Oral Maxillofac Surg. 2013;71(3):513–9.

    PubMed  Google Scholar 

  63. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–99.

    CAS  PubMed  Google Scholar 

  64. Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008;26(36):5904–9.

    PubMed  Google Scholar 

  65. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353(1):99–102; discussion 99.

    CAS  PubMed  Google Scholar 

  66. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case–control study. J Oral Maxillofac Surg. 2008;66(4):625–31.

    PubMed Central  PubMed  Google Scholar 

  67. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab. 2007;92(3):1172–5.

    CAS  PubMed  Google Scholar 

  68. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther. 2007;29(8):1548–58.

    CAS  PubMed  Google Scholar 

  69. Cartsos VM, Zhu S, Zavras AI. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people. J Am Dent Assoc. 2008;139(1):23–30.

    PubMed  Google Scholar 

  70. Malden N, Lopes V. An epidemiological study of alendronate-related osteonecrosis of the jaws.A case series from the south-east of Scotland with attention given to case definition and prevalence. J Bone Miner Metab. 2012;30(2):171–82.

    CAS  PubMed  Google Scholar 

  71. Diniz-Freitas M, Lopez-Cedrun JL, Fernandez-Sanroman J, Garcia-Garcia A, Fernandez-Feijoo J, Diz-Dios P. Oral bisphosphonate-related osteonecrosis of the jaws: clinical characteristics of a series of 20 cases in Spain. Med Oral Patol Oral Cir Bucal. 2012;17(5):e751–8.

    PubMed Central  PubMed  Google Scholar 

  72. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. 2009;67(5 Suppl):61–70.

    PubMed  Google Scholar 

  73. Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol. 2007;4(12):711–21.

    CAS  PubMed  Google Scholar 

  74. Abtahi J, Agholme F, Sandberg O, Aspenberg P. Bisphosphonate-induced osteonecrosis of the jaw in a rat model arises first after the bone has become exposed. No primary necrosis in unexposed bone. J Oral Pathol Med. 2012;41(6):494–9.

    CAS  PubMed  Google Scholar 

  75. Otto S, Hafner S, Mast G, Tischer T, Volkmer E, Schieker M, et al. Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle? J Oral Maxillofac Surg. 2010;68(5):1158–61.

    PubMed  Google Scholar 

  76. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg. 2008;66(5):839–47.

    PubMed Central  PubMed  Google Scholar 

  77. Tsao C, Darby I, Ebeling PR, Walsh K, O’Brien-Simpson N, Reynolds E, et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg. 2013;71(8):1360–6.

    PubMed  Google Scholar 

  78. Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, et al. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma. 2007;48(1):56–64.

    PubMed  Google Scholar 

  79. Aspenberg P. Osteonecrosis of the jaw: what do bisphosphonates do? Expert Opin Drug Saf. 2006;5(6):743–5.

    CAS  PubMed  Google Scholar 

  80. Paparella ML, Brandizzi D, Santini-Araujo E, Cabrini RL. Histopathological features of osteonecrosis of the jaw associated with bisphosphonates. Histopathology. 2012;60(3):514–6.

    PubMed  Google Scholar 

  81. Lesclous P, AbiNajm S, Carrel JP, Baroukh B, Lombardi T, Willi JP, et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone. 2009;45(5):843–52.

    CAS  PubMed  Google Scholar 

  82. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007;65(7):1328–31.

    PubMed  Google Scholar 

  83. Sedghizadeh PP, Jones AC, LaVallee C, Jelliffe RW, Le AD, Lee P, et al. Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(2):224–32.

    PubMed Central  PubMed  Google Scholar 

  84. Sarasquete ME, Garcia-Sanz R, Marin L, Alcoceba M, Chillon MC, Balanzategui A, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. 2008;112(7):2709–12.

    CAS  PubMed  Google Scholar 

  85. Zhong DN, Wu JZ, Li GJ. Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: a meta-analysis. Acta Haematol. 2013;129(2):90–5.

    CAS  PubMed  Google Scholar 

  86. Lai XS, Yang LP, Li XT, Liu JP, Zhou ZW, Zhou SF. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr Drug Metab. 2009;10(9):1009–47.

    CAS  PubMed  Google Scholar 

  87. Such E, Cervera J, Terpos E, Bagan JV, Avaria A, Gomez I, et al. CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica. 2011;96(10):1557–9.

    PubMed Central  PubMed  Google Scholar 

  88. English BC, Baum CE, Adelberg DE, Sissung TM, Kluetz PG, Dahut WL, et al. A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer. Ther Clin Risk Manag. 2010;6:579–83.

    CAS  PubMed Central  PubMed  Google Scholar 

  89. Nicoletti P, Cartsos VM, Palaska PK, Shen Y, Floratos A, Zavras AI. Genomewidepharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist. 2012;17(2):279–87.

    CAS  PubMed Central  PubMed  Google Scholar 

  90. Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res. 2009;24(4):561–74.

    CAS  PubMed  Google Scholar 

  91. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int. 2000;66(2):100–3.

    CAS  PubMed  Google Scholar 

  92. Nishizawa Y, Ohta H, Miura M, Inaba M, Ichimura S, Shiraki M, et al. Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab. 2013;31(1):1–15.

    CAS  PubMed  Google Scholar 

  93. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333(22):1437–43.

    CAS  PubMed  Google Scholar 

  94. Kwon YD, Kim DY, Ohe JY, Yoo JY, Walter C. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(12):2644–8.

    PubMed  Google Scholar 

  95. Lazarovici TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, et al. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg. 2010;68(9):2241–7.

    PubMed  Google Scholar 

  96. Kunchur R, Need A, Hughes T, Goss A. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(6):1167–73.

    PubMed  Google Scholar 

  97. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2008;66(6):1320–1; author reply 1–2.

    PubMed  Google Scholar 

  98. Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, et al. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg. 2009;67(1):159–61.

    PubMed  Google Scholar 

  99. Bilezikian JP, Matsumoto T, Bellido T, Khosla S, Martin J, Recker RR, et al. Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J Bone Miner Res. 2009;24(3):373–85.

    PubMed  Google Scholar 

  100. Don-Wauchope AC, Cole DE. The (mis) use of bone resorption markers in the context of bisphosphonate exposure, dental surgery and osteonecrosis of the jaw. Clin Biochem. 2009;42(10–11):1194–6.

    CAS  PubMed  Google Scholar 

  101. Cremers S, Farooki A. Biochemical markers of bone turnover in osteonecrosis of the jaw in patients with osteoporosis and advanced cancer involving the bone. Ann N Y Acad Sci. 2011;1218:80–7.

    CAS  PubMed  Google Scholar 

  102. Kim JW, Kong KA, Kim SJ, Choi SK, Cha IH, Kim MR. Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates. Bone. 2013;57(1):201–5.

    CAS  PubMed  Google Scholar 

  103. Choi SY, An CH, Kim SY, Kwon TG. Bone turnover and inflammatory markers of bisphosphonate-related osteonecrosis of the jaw in female osteoporosis patients. J Oral Maxillofac Surg Med Pathol. 2013;25:123–8.

    Google Scholar 

  104. Lopez-Carrizosa MC, Samper-Ots PM, Perez AR. Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases. Clin Transl Oncol. 2010;12(8):568–73.

    CAS  PubMed  Google Scholar 

  105. Kimmel DB, Recker RR, Gallagher JC, Vaswani AS, Aloia JF. A comparison of iliac bone histomorphometric data in post-menopausal osteoporotic and normal subjects. Bone Miner. 1990;11(2):217–35.

    CAS  PubMed  Google Scholar 

  106. Silva I, Branco JC. Rank/Rankl/opg: literature review. Acta Reumatol Port. 2011;36(3):209–18.

    CAS  PubMed  Google Scholar 

  107. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–22.

    CAS  PubMed Central  PubMed  Google Scholar 

  108. Anghel R, Bachmann A, Beksac M, Brodowicz T, Finek J, Komadina R, et al. Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. Wien Klin Wochenschr. 2013;125(15–16):439–47.

    CAS  PubMed  Google Scholar 

  109. Body JJ. Inhibition of RANK Ligand to treat bone metastases. Bull Cancer. 2013;100(11):1207–13.

    CAS  PubMed  Google Scholar 

  110. Silva I, Branco JC. Denosumab: recent update in postmenopausal osteoporosis. Acta Reumatol Port. 2012;37(4):302–13.

    PubMed  Google Scholar 

  111. Pazianas M. Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst. 2011;103(3):232–40.

    PubMed  Google Scholar 

  112. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082–92.

    CAS  PubMed  Google Scholar 

  113. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564–71.

    CAS  PubMed  Google Scholar 

  114. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007;25(28):4431–7.

    CAS  PubMed  Google Scholar 

  115. Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745–55.

    CAS  PubMed Central  PubMed  Google Scholar 

  116. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23(5):1341–7.

    CAS  PubMed  Google Scholar 

  117. Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol. 2013;20.

    Google Scholar 

  118. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwinski E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694–701.

    CAS  PubMed Central  PubMed  Google Scholar 

  119. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14(9):901–8.

    CAS  PubMed  Google Scholar 

  120. Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat. 2009;116(3):433–9.

    CAS  PubMed  Google Scholar 

  121. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002;2(10):727–39.

    CAS  PubMed  Google Scholar 

  122. Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg. 2013;71(9):1532–40.

    PubMed  Google Scholar 

  123. Greuter S, Schmid F, Ruhstaller T, Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol. 2008;19(12):2091–2.

    CAS  PubMed Central  PubMed  Google Scholar 

  124. Koch FP, Walter C, Hansen T, Jager E, Wagner W. Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg. 2011;15(1):63–6.

    PubMed  Google Scholar 

  125. Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone. 2004;35(5):1144–56.

    CAS  PubMed  Google Scholar 

  126. Troeltzsch M, Woodlock T, Kriegelstein S, Steiner T, Messlinger K. Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc. 2012;78:c85.

    PubMed  Google Scholar 

  127. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G, 3rd, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008 20;26(24):4037–8.

    Google Scholar 

  128. Guarneri V, Miles D, Robert N, Dieras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010;122(1):181–8.

    CAS  PubMed  Google Scholar 

  129. Disel U, Besen AA, Ozyilkan O, Er E, Canpolat T. A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. Oral Oncol. 2012;48(2):e2–3.

    PubMed  Google Scholar 

  130. Hopp RN, Pucci J, Santos-Silva AR, Jorge J. Osteonecrosis after administration of intravitreous bevacizumab. J Oral Maxillofac Surg. 2012;70(3):632–5.

    PubMed  Google Scholar 

  131. Santos-Silva AR, Belizario Rosa GA, Castro Junior G, Dias RB, Prado Ribeiro AC, Brandao TB. Osteonecrosis of the mandible associated with bevacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(6):e32–6.

    PubMed  Google Scholar 

  132. Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology. 2009;76(3):209–11.

    CAS  PubMed  Google Scholar 

  133. Hoefert S, Eufinger H. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(4):463–9.

    PubMed  Google Scholar 

  134. Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, et al. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer. 2012;48(7):1031–7.

    CAS  PubMed  Google Scholar 

  135. Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer. 2012;107(10):1665–71.

    CAS  PubMed Central  PubMed  Google Scholar 

  136. Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113(3):e1–3.

    PubMed  Google Scholar 

  137. Nicolatou-Galitis O, Migkou M, Psyrri A, Bamias A, Pectasides D, Economopoulos T, et al. Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113(2):234–8.

    PubMed  Google Scholar 

  138. Kim DW, Jung YS, Park HS, Jung HD. Osteonecrosis of the jaw related to everolimus: a case report. Br J Oral Maxillofac Surg. 2013;51(8):e302–4.

    PubMed  Google Scholar 

  139. Ayllon J, Launay-Vacher V, Medioni J, Cros C, Spano JP, Oudard S. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? Ann Oncol. 2009;20(3):600–1.

    CAS  PubMed  Google Scholar 

  140. Serra E, Paolantonio M, Spoto G, Mastrangelo F, Tete S, Dolci M. Bevacizumab-related osteneocrosis of the jaw. Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):1121–3.

    Google Scholar 

Download references

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Science, and Technology (NRF 2010-0011-445).

Author information

Authors and Affiliations

  1. Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyungpook National University, Samduck 2 Ga, Jungu, Daegu, 700-412, Republic of Korea

    Tae-Geon Kwon DDS, PhD

Authors
  1. Tae-Geon Kwon DDS, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tae-Geon Kwon DDS, PhD .

Editor information

Editors and Affiliations

  1. Department of Oral and Maxillofacial Sur, Ludwig-Maximilians-University of Munich, Munich, Germany

    Sven Otto

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kwon, TG. (2015). Risk Factors for Medication-Related Osteonecrosis of the Jaw. In: Otto, S. (eds) Medication-Related Osteonecrosis of the Jaws. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43733-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43733-9_3

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43732-2

  • Online ISBN: 978-3-662-43733-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation